The abstracts for the forthcoming American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium (ASCO GU) have been released and offer insight into some of the new data that will be presented at the meeting.

radium-223 Alpharadin Prostate CancerThe results of the phase III ALSYMPCA trial for radium-223 (Alpharadin) in prostate cancer were presented at ECCO/ESMO last September by Dr Chris Parker.

As expected, there is no change to data presented in Stockholm that showed radium-223 (Alpharadin) improves both Overall Survival and Skeletal Related Events:

radium-223 Overall Survival Benefit
median 14.0 vs 11.2 months; P value = 0.00185; HR = 0.695

radium-223 time to first SRE 
median 13.6 vs 8.4 months; P value = 0.00046; HR = 0.610

However, the meeting abstract published today shows that radium-223 in bone-metastatic castration resistant prostate cancer patients (CRPC), not only significantly prolonged time to first skeletal related event (SRE), but significantly prolonged 3 out of the 4 SRE components:

  • time to spinal cord compression,
  • time to pathological bone fracture
  • time to external beam radiation

No significant improvement in the SRE component of time to surgical intervention was seen with radium-223.

Subscribers to Premium Content can login to read commentary by Dr Oliver Sartor on the clinical significance of this data:

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. You are NOT PERMITTED to share access or copies of posts. If you wish to purchase a CORPORATE or MULTI-USER license or want to be able to share content PLEASE CONTACT US to purchase this. Please read the terms of use before purchasing & if you work in PR, Communications or for an agency, the guidance within it. The $999 Black Friday Sale rate is only available until 1pm Eastern Time on Nov 28, 2015. Rates may change without notice and are non-refundable.